Matthew Brunner, MHS, PA-C, DFAAPA

Matthew Brunner, MHS, PA-C, DFAAPA, highlights the most anticipated developments in the field of treating patients with plaque psoriasis.

Stratification of patients for the treatment of plaque psoriasis based on comorbidities and prior biologic experience.

Advanced practice providers discuss scenarios in which they would consider switching between therapies when treating patients with plaque psoriasis.

Lakshi Aldredge, MSN, ANP-BC, DCNP, and Matthew Brunner, MHS, PA-C, DFAAPA share their personal experiences with using IL-23 inhibitors in treating patients with plaque psoriasis.

Mechanism of action and dosing of IL-23 inhibitors use to treat plaque psoriasis as explained by advanced practice providers.

IL-17 inhibitors and IL-12/23 inhibitors used in the treatment of plaque psoriasis.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, share their experiences with tumor necrosis factor (TNF) inhibitors in treating plaque psoriasis.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, discuss factors leading to transition from topical agents to oral systemic therapies for plaque psoriasis.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, review use of nonbiologic oral systemic agents (eg, apremilast, methotrexate, acitretin) in the management of plaque psoriasis.

Matthew Brunner, MHS, PA-C, DFAAPA, and Lakshi Aldredge, MSN, ANP-BC, DCNP, discuss the current role of topical medications as the standard of care for initial therapy in plaque psoriasis.

Lifestyle modification and counseling to help manage flare-ups resulting from triggers for plaque psoriasis.

Diagnosis and management of plaque psoriasis as discussed by advanced practice providers.

Advanced practice providers share their perspectives on assessing and grading the disease severity of plaque psoriasis.

The clinical and psychological impact of plaque psoriasis on a patient’s overall well-being.